These patients had not yet received CAR T cell therapy and were compared with peripheral blood samples from CLL patients (CD19+/CD5+ gated) and from healthy donors (CD19+/CD20+ gated), both of which showed no notable surface expression of CD80/CD86. This evidence concerns the gene CD86 and B-cell chronic lymphocytic leukemia.